Citi Reiterates Neutral Rating on Arrowhead Pharma (ARWR)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall Street rallies as Fed's Waller eases rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
June 3, 2024 7:30 AM EDT- Plozasiran achieved statistically significant median reductions in triglycerides up to 80% and mean reductions in APOC3 up to 94% at month 10
- Plozasiran achieved a statistically significant reduction in incidence of acute pancreatitis versus placebo
- Plozasiran is the companys first investigational RNAi-based therapy to show clinical efficacy in a Phase 3 study
- Arrowhead plans to highlight recent data for its cardiometabolic pipeline at its June 25, 2024, Cardiometabolic event as part of... More
Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
May 31, 2024 7:30 AM EDTPASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
16th European Glaucoma Society (EGS) Congress June 1-4, 2024
Title: Development and Characterization of Trabecular Meshwork Targeted RNAi Molecule Platform via Intracameral Administration for Glaucoma
Date/Time: June 2, 2024, 10:30 a.m. IST
Session: Poster Section
Jefferies Global Healthcare Conference June 5-6, 2024
Type: Fireside Chat Presentation
Date/Time: June 5, 2024, 12:30 p.m. EDT
European Association for the Study of the Liver (EASL) Congress 2024 June 5-8,... More
